Junshi Biosciences: Focused on developing therapies in I-O, autoimmune and metabolic diseases. 13 pipeline candidates (7 in I-O, 2 in metabolic, 3 in autoimmune and 1 in neurological diseases). JS001, or toripalimab, is approved by the NMPA and the first marketed anti-PD-1 mAb antibody self-developed by a PRC company. For full year 2019, toripalimab sales were approximately $11.1M / 135,525 bottles.
Biotech Company / Healthcare/Biotechnology
Based in...
Clinical Stage
Phase III, Registration Stage
Disease Space
Autoimmune, Immuno-Oncology, Metabolic Disorders
Biotechnology, Pharmaceuticals
Public, ROW
Market Cap
1B +
Therapeutic Modalities
Antibodies, Platform Technology
Floor 13, Building 2, Nos. 36 and 58, Haiqu Road
Pudong , Shanghai 201203

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.